Gastric protein comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-21. Numbers and descriptions here follow the published literature rather than marketing material.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Color markers are sometimes added to loading dyes for gel electrophoresis in the separation of DNA fragments. Loading dyes keep DNA samples below the surface of the agarose gel, and the color markers within help keep track of the migration front of the DNA as it moves along the gel. For PAGE, some commercially available molecular weight markers (also called "ladders" because they look like the rungs of a ladder after separation) contain pre-stained proteins of different colours, so it is possible to determine more accurately where the proteins of interest in the samples might be.
== Protein degradation == Protein degradation differs from protein catabolism. Proteins are produced and destroyed routinely as part of the normal operations of the cell. Transcription factors, proteins that help regulate protein synthesis, are targets of such degradations. Their degradation is not a significant contributor to the energy needs of the cell. The addition of ubiquitin (ubiquitylation) marks a protein for degradation via the proteasome.
== Chemistry and animal toxicology == Buformin hydrochloride is a fine, white to slightly yellow, crystalline, odorless powder, with a weakly acidic bitter taste. Its melting point is 174 to 177 °C, it is a strong base, and is freely soluble in water, methanol and ethanol, but insoluble in chloroform and ether. The log octanol-water partition coefficient (log P) is -1.20E+00 and its water solubility is 7.46E+05 mg/L at 25 °C. Vapor pressure is 1.64E-04 mm Hg at 25 °C (EST); Henry's law constant is 8.14E-16 atm-m3/mole at 25 °C (EST). Its Atmospheric -OH rate constant is 1.60E-10 cm3/molecule-sec at 25 °C.
== Standard structure == The amino acids in a standard π-helix are arranged in a right-handed helical structure. Each amino acid corresponds to an 87° turn in the helix (i.e., the helix has 4.1 residues per turn), and a translation of 1.15 Å (0.115 nm) along the helical axis. Most importantly, the N-H group of an amino acid forms a hydrogen bond with the C=O group of the amino acid five residues earlier; this repeated i + 5 → i hydrogen bonding defines a π-helix. Similar structures include the 310 helix (i + 3 → i hydrogen bonding) and the α-helix (i + 4 → i hydrogen bonding).
Bhutan: Starting primarily in the 1990s, the Bhutanese government implemented strict restrictions on the country's ethnically Nepali Lhotshampa population and implemented internal border control policies to restrict immigration or return of ethnic Nepalis, creating a refugee crisis. This policy shift effectively ended previously liberal immigration policies concerning Nepalis and counts among the most racialised border control policies in Asia. China: China does not currently recognise North Korean defectors as refugees and subjects them to immediate deportation if caught. The China-DPRK border is fortified, and both sides aim to deter refugees from crossing. Human rights organisations have criticised this aspect of Chinese border control policy. Cyprus: As a result of Northern Cyprus's sovereignty dispute with Southern Cyprus, the South (a member of the European Union) has imposed restrictions on the North's airports, and pressure from the European Union has resulted in all countries other than Turkey recognising the South's ability to impose a border shutdown on the North, thus negating the right to self determination of the predominantly Turkish Northern Cypriot population and subjecting their airports to border controls imposed by the predominantly Greek South. As a result, Northern Cyprus is heavily dependent on Turkey for economic support and is unable to develop a functioning economy. Israel: Border control, both on entry and on exit, at Israeli airports rates passengers' potential threat to security using factors including nationality, ethnicity, and race.
Sources: en.wikipedia.org
persistence 1. The tendency of a moving cell to continue moving in the same direction as previously; that is, even in isotropic environments, there inevitably still exists an inherent bias by which, from instant to instant, cells are more likely not to change direction than to change direction. Averaged over long periods of time, however, this bias is less obvious and cell movements are better described as a random walk. 2. The ability of some viruses to remain present and viable in cells, organisms, or populations for very long periods of time by any of a variety of strategies, including retroviral integration and immune suppression, often in a latent form which replicates very slowly or not at all.
=== Scholarly articles === Barron, Lee. "Pulling Down Barriers: Neil Peart, Autobiographical Confession and Negotiated Rock Celebrity", Celebrity Studies, Vol. 7 No. 3, 2016, pp. 323–338. Bowman, Durrell S. "Let Them All Make Their Own Music: Individualism, Rush and the Progressive / Hard Rock Alloy", in Progressive Rock Reconsidered, Kevin Holm-Hudson (ed), Routledge, 2002. Connolly, T. "Mean, Mean Pride: Rush's Critique of American Cool", in T. Connolly and T. Iino (eds), Canadian Music and American Culture. Palgrave MacMillan, 2017. Friedman, Jonathan C. "Performing Grief: The Music of Three Children of Holocaust Survivors: Geddy Lee, Yehuda Poliker, and Mike Brant", Journal of Modern Jewish Studies, Vol. 16 No. 1, 2017, pp. 153–167. Horwitz, Steve. "Rand, Rush, and De-totalizing the Utopianism of Progressive Rock", Journal of Ayn Rand Studies, Vol. 5 No. 1, Fall 2003, pp. 161–172. McDonald, Chris. "Grand Designs: A Musical, Social and Ethnographic Study of Rush", PhD dissertation in ethnomusicology, York University, 2002. McDonald, Chris. "'Making Arrows Out of Pointed Words': Critical Reception, Taste Publics and Rush", Journal of American and Comparative Cultures, Volume 25 No. 3-4, September 2002, pp. 249–259. McDonald, Chris. "'Open Secrets': Individualism and Middle-Class Identity in the songs of Rush", Popular Music and Society Volume 31 No. 3, July 2008, pp. 313–328. Sciabarra, Chris. "Rush, Rand and Rock", Journal of Ayn Rand Studies, Vol. 4 No. 1, Fall 2002, pp. 161–185. Walsh, Brian.
In Normandy, the 82nd gained its first Medal of Honor of the war, belonging to Private first class Charles N. DeGlopper of the 325th GIR. When the division was relieved in early July, the 82nd had seen a month straight of severe combat. Casualties were heavy. Losses included 5,245 troopers killed, wounded, or missing- a 46% casualty rate. Major General Ridgway's post-battle report stated in part, "... 33 days of action without relief, without replacements. Every mission accomplished. No ground gained was ever relinquished." Following Normandy, the 82nd Airborne Division returned to England to rest and refit for future airborne operations. The 82nd became part of the newly organized XVIII Airborne Corps, which consisted of the 17th, 82nd, and 101st Airborne Divisions. Ridgway was given command of the corps but was not officially promoted to lieutenant general until 1945. His recommendation for succession as division commander was Brigadier General James M. Gavin, previously the 82nd's assistant division commander. Upon being promoted to major general in October 1944 at the age of 37, Gavin became the youngest general since the Civil War to command a US Army division.
Legal proceedings involving UCC, the United States and Indian governments, local Bhopal authorities, and the disaster victims started immediately after the catastrophe. The Indian Government passed the Bhopal Gas Leak Act in March 1985, allowing the Government of India to act as the legal representative for victims of the disaster, leading to the beginning of legal proceedings. Initial lawsuits were generated in the United States federal court system. On 17 April 1985, Federal District court judge John F. Keenan (overseeing one lawsuit) suggested that "'fundamental human decency' required Union Carbide to provide between $5 million and $10 million to immediately help the injured" and suggested the money could be quickly distributed through the International Red Cross. UCC, on the notion that doing so did not constitute an admission of liability and the figure could be credited toward any future settlement or judgement, offered a $5 million relief fund two days later. The Indian government turned down the offer. In March 1986, UCC proposed a settlement figure, endorsed by plaintiffs' U.S. attorneys, of $350 million that would, according to the company, "generate a fund for Bhopal victims of between $500–600 million over 20 years". In May, litigation was transferred from the United States to Indian courts by a U.S. District Court ruling. Following an appeal of this decision, the U.S. Court of Appeals affirmed the transfer in November 1986, judging that UCIL was a "a separate and independent legal entity, managed and operated exclusively by Indian citizens in India".
== Adverse events == In 2005, the FDA announced that they were investigating reports of death and other serious adverse events related to narcotic overdose in patients using Duragesic, the fentanyl transdermal patch for pain control. The Duragesic product label was subsequently updated to add safety information in June 2005. In 2007, Shire and Noven Pharmaceuticals, manufacturers of the Daytrana ADHD patch, announced a voluntary recall of several lots of the patch due to problems with separating the patch from its protective release liner. Since then, no further problems with either the patch or its protective packaging have been reported. In 2008, two manufacturers of the fentanyl patch, ALZA Pharmaceuticals (a division of major medical manufacturer Johnson & Johnson) and Sandoz, subsequently issued a recall of their versions of the patch due to a manufacturing defect that allowed the gel containing the medication to leak out of its pouch too quickly, which could result in overdose and death. As of March 2009, Sandoz—now manufactured by ALZA—no longer uses gel in its transdermal fentanyl patch; instead, Sandoz-branded fentanyl patches use a matrix/adhesive suspension (where the medication is blended with the adhesive instead of held in a separate pouch with a porous membrane), similar to other fentanyl patch manufacturers such as Mylan and Janssen. In 2009, the FDA announced a public health advisory warning of the risk of burns during MRI scans from transdermal drug patches with metallic backings.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.